Diagnostic utility of serological biomarkers in patients with Crohn's disease: A case-control study
- PMID: 30095633
- PMCID: PMC6133474
- DOI: 10.1097/MD.0000000000011772
Diagnostic utility of serological biomarkers in patients with Crohn's disease: A case-control study
Abstract
The aim of this study was to examine the expression of serological markers in patients with inflammatory bowel disease in China, and determine the diagnostic utility of serological markers, individually and in combination, for the diagnosis and differential diagnosis of Crohn's disease (CD).Serum samples were obtained from 160 participants in Eastern China. Among the participants, 98 were diagnosed with CD, 33 had ulcerative colitis (UC), and 29 were healthy controls (HC). The serum samples were tested for the presence of antibodies against outer membrane porin C (anti-OmpC), Pseudomonas fluorescens bacterial sequence I2 (anti-I2), anti-laminarin (anti-L), anti-chitin (anti-C), anti-chitobioside carbohydrate antibody (ACCA), anti-laminaribioside carbohydrate antibody (ALCA), anti-mannobioside carbohydrate antibody (AMCA), and anti-Saccharomyces cerevisiae antibody (ASCA) by indirect enzyme-linked immunosorbent assay (ELISA).Individually, anti-C, anti-L, ASCA-IgG, and ALCA lacked diagnostic value in the differentiation of CD. ASCA-IgA remained the most accurate marker for the diagnosis of CD, with an area under the curve (AUC) of 0.77; however, its sensitivity and specificity were both lower than 75%. Among the combinations of the 5 markers with significant diagnosing ability for CD, combinations with any 2 of the 3 markers, ASCA IgA, AMCA, and ACCA positive, provided the best accuracy in the diagnosis and differential diagnosis of CD (sensitivity and specificity both above 75%) and had the highest Youden index.Serological antibodies, when considered in combination, have remarkable value in the diagnosis and differential diagnosis of CD. Especially, the combination of any 2 of the 3 markers, ASCA-IgA, AMCA, ACCA positive, appears to be optimal.
Conflict of interest statement
Conflict-of-interest statement: We declare that we have no financial or personal relationships with other individuals or organizations that would inappropriately influence our work. There is no professional or other personal interest of any nature in any product or service.
Figures






References
-
- De Souza HSP. Etiopathogenesis of inflammatory bowel diseases: today and tomorrow. Curr Opin Gastroenterol 2017;33:222–9. PMID: 28402995. - PubMed
-
- Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417–29. PMID: 12167685. - PubMed
-
- Dotan I, Fishman S, Dgani Y, et al. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease. Gastroenterology 2006;131:366–78. PMID: 16890590. - PubMed
-
- Reumaux D, Sendid B, Poulain D, et al. Serological markers in inflammatory bowel diseases. Best Pract Res Clin Gastroenterol 2003;17:19–35. PMID: 12617880. - PubMed
-
- Rutgeerts P, Vermeire S. Clinical value of the detection of antibodies in the serum for diagnosis and treatment of inflammatory bowel disease. Gastroenterology 1998;115:1006–9. PMID: 9786723. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical